3.Techniques for assessing myocardial reperfusion after acute myocardial infarction
Journal of Interventional Radiology 1994;0(04):-
TIMI Flow as a method to assess myocardial reperfusion has been employed clinically ever since 1980's.TIMI Frame Count grading is a more objective,repeatable and correlative in variablity than those of TIMI Flow.TMBG and TMP provide the reperfusion evaluation on myocardial microvascular level.Doppler contrast echocardiography could be used as an additional index to assess vessel recanalization and myocardial reperfusion.Moreover,MCE,continuous ECG monitoring of ST-segment,isotope imaging of myocardial reperfusion and myocardial-enhanced MRI can all be used as non-invasive evaluating approaches with great clinical value.(J Intervent Radiol,2006,15:250-253)
7.Effect of percutaneous coronary intervention in patients with coronary artery disease over 75 years old
Jieyan SHEN ; Ben HE ; Jianping LIU
Chinese Journal of Interventional Cardiology 2003;0(06):-
Objective To explore the therapeutic effect of percutaneous coronary intervention in patients with coronary artery disease over 75 years old. Methods Patients underwent percutaneous coronary interventions (PCI) during the period from April 2001 to April 2004 were divided into the elder group (age ≥75 years old) and the younger group (age ≤60 years old). The basic characteristics, immediate success rate and the incidence of major adverse cardiac events (MACE) such as re-angioplasty, myocardial infarction and cardiac death during follow-up were analyzed between the two groups. Results The elder group had enrolled 81 cases (64 male/17 female), while the younger group had enrolled 196 cases (176 male/20 female). History of hypertension, cardiac dysfunction, pulmonary disease, kidney dysfunction and cerebral vascular disease was more commonly found in the elder group. Compared with the younger group, the elder patients were more likely to have multi-vessels lesions (46.9% vs 15.3%, P
8.Naloxone can reverse blunted baroreflex sensitivity after acute myocardial infarction
Ben HE ; Daosheng ZHENG ; Yixian WU
Chinese Pharmacological Bulletin 1987;0(02):-
Acute myocardial infarction (AMI) model was made in SD rats by coronary ligation, the effects of naloxone (Nal) on the baroreflex sensitivity (BRS) were evaluated by administrated Nal intravenously (iv) and in-tracisternally (ic) before and after 1 h of AMI.Results showed that both pre and post AMI can Nal potentiate the BRS whether iv or ic. These results indicate that Nal may reverse the blunted BRS after AMI.
9.EMMPRIN mediates matrix metalloproteinase 9 expression and monocyte migration: evidence from EMMPRIN knockdown by RNA interference
Qing HE ; Changqian WANG ; Heng GE ; Junfeng ZHANG ; Ben HE
Chinese Journal of Pathophysiology 2010;26(3):466-471
AIM: Although the evidence indicates that extracellular matrix metalloproteinase inducer (EMMPRIN) is closely associated with matrix metalloproteinase (MMP) expression in tumor cells, tumor invasion and metastasis, no direct proof that EMMPRIN regulates MMPs in monocytes, especially in the atherogenic milieu is observed. Here we tested this hypothesis by examining MMP-9 expression in macrophages/foam cells and monocyte migration through EMMPRIN knockdown by siRNA. METHODS: The methods of qPCR and Western blotting were used to detect the suppressions of EMMPRIN mRNA and protein expression in macrophages and foam cells transfected with EMMPRIN-specific siRNA. The protein expression of MMP-9 in macrophages and foam cells was also determined. Monocyte migration after EMMPRIN knockdown was observed by a Transwell assay. RESULTS: EMMPRIN knockdown by siRNA markedly abolished the MMP-9 expression by 50% and 40% in macrophages and foam cells, respectively. Migration induced by chemotactic factor MCP-1 and VEGF was significantly attenuated (P<0.05) in monocytes treated with EMMPRIN-siRNA. CONCLUSION: The protein expression and secretion of MMP-9 are down-regulated by EMMPRIN knockdown during monocyte differentiation into macrophages and foam cells. Moreover, EMMPRIN siRNA treatment also prevents monocyte migration. Thus, EMMPRIN plays a key regulatory role for MMP activity and monocyte migration, making it a potential target for pharmacological intervention of atherosclerosis.